Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Amit Sanyal, MD: A Clinician’s Perspective

Advertisement

Advertisement




Oct
28
Today In Oncology
Expert Histopathology and Molecular Testing Improve Diagnosis of Ambiguous Cutaneous Melanocytic Tumors
Radiation Added to Systemic Therapy Improves PFS But Not OS for Oligometastatic NSCLC
Is Enucleation a Safe Alternative to Pancreatoduodenectomy for Benign or Low-Grade Pancreatic Head Tumors
Impact of Digital Breast Tomosynthesis on Invasive Interval Breast Cancer Rate
Divarasib in Previously Treated Advanced KRAS G12C–Mutated NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo